AUTHORS
Sydney Aikens, Bayard Powell, MD2, Leslie Ellis Jr, MD3, Matthew Joseph Wieduwilt, MD, PhD4, Madelyn Burkart, MD5, Megan Manuel, NP6, Sarah Dralle, NP7, Susan Lyerly, PA-C8, Michael R. Grunwald, MD9, Brittany Knick Ragon, MD10, Thomas G Knight, MD11, Aleksander Chojecki, MD12, Srinivasa Sanikommu, MD13, Nilay Shah, MD14, Kelly Weaver, NP15, Jing Ai, MD, PhD16, Rupali Roy Roy Bhave, MD17, Giovanni Insuasti-Beltran, MD18, Timothy Pardee, MD, PhD19
AFFILIATIONS
1 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
2 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
3 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
4 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
5 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
6 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
7 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
8 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
9 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
10 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
11 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
12 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
13 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
14 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
15 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
16 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
17 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
18 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
19 Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
ABSTRACT
Background/objective: Previous datasets show TP53-mutated myeloid diseases are associated with poor outcomes. We evaluated the clinical outcomes and characteristics of TP53-mutated AML and MDS in a real-world cohort at our cancer center.
Methods: Retrospective cohort study of 247 TP53-mutated patients identified from results of our internal myeloid neoplasm NGS panel at Atrium Health Wake Forest Baptist Comprehensive Cancer Center between May 2024 - May 2026. Of these, 182 patients were diagnosed with AML or MDS. Data was obtained from the medical record. We collected data on patient age, co-morbidities, previous history of cancer, family history of cancer, karyotype, number and type of mutations, treatment type including receipt of allogeneic stem cell transplant and survival.
Disease characteristics were assessed with descriptive statistics. Overall survival (OS) was estimated using the Kaplan-Meier method and compared between groups using log-rank testing. We used univariable and multivariable Cox proportional hazards regression analyses to explore factors independently associated with survival outcomes including age, disease (MDS vs AML), number of TP53 mutations, karyotype (complex vs not), and treatment regimen.
Results:
Of the 182 TP53-mutated patients, 78 had MDS and 104 had AML. The median age at diagnosis was 74 years (range 21-94), and 103 (56.6%) patients were male. Family history for cancer was positive in 92 (50.5%) patients. A personal history of cancer was positive in 83 (45.6%) patients. Comorbidities were assessed using the Charleson comorbidity index, 71 patients had a score of 0, 70 patients scored between 1-3, and 31 patients >3. The median Charlson comorbidity score was 1 (range 0-8). Of 87 patients with performance status documented at diagnosis, 45 had an ECOG PS of 0 or 1 and 42 had an ECOG ≥2. Karyotype from bone marrow biopsy at initial diagnosis was documented for 162 patients including 130 patients with a complex karyotype, 17 with non-complex abnormal karyotype, and 15 with a normal karyotype.
Next-generation sequencing from bone marrow biopsy at initial diagnosis was available for 178 patients. Only 3 patients lacked a TP53 mutation on initial biopsy. Four patients were noted to have 3 or 4 different TP53 mutations. The most common co-mutations were ASXL1 (14), TET2 (13), DNMT3A (12), NF1 (11), SRSF2 (11), and SF3B1 (11). When considering all mutations, 64 patients had a TP53 mutation only, 61 patients had one additional mutation, and 53 had ≥2 additional mutations.
Median OS for the combined AML and MDS patient cohort was 301 days (95%CI 222-373). OS was worse in AML compared to MDS (HR 2.258, P=0.0001) with median OS of 177 days in AML (95%CI 122-281), compared to 486 days in MDS (95%CI 364-630). In AML and MDS combined, complex karyotype was associated with lower OS than non-complex (HR 3.782, P<0.0001) with median OS of 281 days in complex versus 1,299 days in non-complex karyotype patients.
We compared outcomes of the AML patients in the cohort treated with azacitidine (15 patients), azacitidine plus venetoclax (37), decitabine (12), and decitabine plus venetoclax (11). In a univariate analysis, single-agent azacitidine was associated with worse OS when compared to single-agent decitabine (HR 4.637, [95% CI 1.557–14.50, P=0.0061]). Median OS in those treated with azacitidine was 139 days, compared to 291 days in the decitabine treatment group. There was no significant difference in survival between patients who received single agent hypomethylating agents and those who received them with venetoclax (p=0.4164). Patients who received no treatment (supportive care, palliative or hospice) had worse OS (HR 6.950, P=0.0001). Of 104 AML patients, only 7 (6.6%) patients received bone marrow transplants.
Conclusion:
Our findings suggest that TP53-mutation in MDS or AML confers a dismal outcome. OS was significantly worse in AML compared to MDS, and in patients with complex karyotypes compared to non-complex. Not surprisingly, AML patients receiving no treatment had worse outcomes compared to those receiving therapy. Notably, AML patients receiving single agent decitabine had a significantly better overall survival in comparison with azacitidine treatment. These findings support the importance of investigating novel approaches for patients with TP53-mutated myeloid disease.
DISCLOSURES
Sydney Aikens: No relevant conflicts of interest to declare.